UNSPSC 51401540: Nimetazepam

This classification denotes a benzodiazepine with the molecular formula C16H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4532264KW6, chemically known as 1,3-dihydro-1-methyl-7-nitro-5-phenyl-2h-1,4-benzodiazepin-2-one but generally known as nimetazepam, which bears US NIH Compound Identifier 4496. European Medicines Agency schedules Nimetazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09295MIG.

UNSPSC 51401540 Nimetazepam is a Commodity code that nominally addresses a specific pharmaceutical product, but recent state and local opportunities under this code show little connection to nimetazepam itself. Instead, the code has tagged solicitations for naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program infrastructure. State and local buyers are using this code to source emergency medical supplies, broad-spectrum pharmaceutical inventories, and pharmacy benefit management services rather than the narrow product class the code name suggests. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of Minnesota Department of Administration and participating jurisdictions including Oregon). The scope reflects public health emergency response, routine pharmaceutical supply, and pharmacy network optimization rather than a single chemical entity.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon based on recent postings. Seminole County, Florida released an IFB on June 30, 2026 (due July 26, 2023, date mismatch in source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, including shipping costs in pricing. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, structured as an exploratory market-intelligence phase preceding formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain $5,000,000 commercial general liability and $2,000,000 network security and privacy liability insurance. Code activity is sparse and mismatch-prone; verify actual scope alignment before pursuing opportunities tagged under this code.